Assessment of Infantile Hemangiomas Using a Handheld Wireless Diffuse Optical Spectroscopic Device

Pediatr Dermatol. 2017 Jul;34(4):386-391. doi: 10.1111/pde.13150. Epub 2017 May 26.

Abstract

Background/objectives: Infantile hemangiomas (IHs) are vascular tumors with the potential for significant morbidity. There is a lack of validated objective tools to assess IH severity and response to treatment. Diffuse optical spectroscopy (DOS), a noninvasive, nonionizing imaging modality, can measure total hemoglobin concentration and hemoglobin oxygen saturation in tissue to assess IH vascularity and response to treatment. Our objective was to evaluate the utility of a wireless, handheld DOS system to assess IH characteristics at selected points during their clinical course.

Methods: Thirteen subjects (initial age 5.8 ± 2.0 mos) with 15 IHs were enrolled. IHs were classified as proliferative, plateau phase, or involuting. Nine patients with 11 IHs were untreated; four patients with 4 IHs were treated with timolol or propranolol. Each IH was evaluated by placing the DOS system directly on the lesion as well a normal contralateral skin site. IH vascularity and oxygenation were scored using a newly defined normalized hypoxia fraction (NHF) coefficient. Measurements were recorded at various intervals from the initial visit to 1 to 2 years of age.

Results: For the nine untreated IHs, the NHF was highest at 6 months of age, during proliferation. Differences in NHFs between the proliferation and the plateau (p = 0.02) and involuting (p < 0.001) stages were statistically significant. In treated patients, the NHF normalized to 60% after 2 months. One treated IH came within 5% of the NHF for normal skin after 12 months.

Conclusions: DOS can be used to assess the vascularity and tissue oxygenation of IHs and monitor their progression and response to treatment.

Publication types

  • Clinical Trial

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Hemangioma / diagnostic imaging*
  • Hemangioma / drug therapy
  • Humans
  • Infant
  • Longitudinal Studies
  • Pilot Projects
  • Spectroscopy, Near-Infrared / methods*
  • Wireless Technology

Substances

  • Adrenergic beta-Antagonists